Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. - Wikidata - awgldk - TriplyDB

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.

http://www.wikidata.org/entity/Q40198053

about

Tyrosine kinase inhibitors for unresectable hepatocellular carcinoma in adults Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma Progress in the treatment of pulmonary metastases after liver transplantation for hepatocellular carcinoma Current and future treatments for hepatocellular carcinoma Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update Chloroquine and hydroxychloroquine for cancer therapy Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up Recent advances in multidisciplinary management of hepatocellular carcinoma Targeting autophagy for the treatment of liver diseases Molecular mechanism and treatment of viral hepatitis-related liver fibrosis.Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma Challenges of advanced hepatocellular carcinoma Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948)Therapeutic evaluation of sorafenib for hepatocellular carcinoma using contrast-enhanced ultrasonography: Preliminary result.Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.Signal integration and gene induction by a functionally distinct STAT3 phosphoform.Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study Multidisciplinary management of hepatocellular carcinoma in clinical practice.Sorafenib cardiotoxicity increases mortality after myocardial infarction.Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.Vascular endothelial growth factor receptor-1 mRNA overexpression in peripheral blood as a useful prognostic marker in breast cancer Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3 Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy.Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma.Correlation of perfusion MRI and 18F-FDG PET imaging biomarkers for monitoring regorafenib therapy in experimental colon carcinomas with immunohistochemical validation.

P2860

Q24187730-53C74746-5718-45CA-B2AF-48B3D145E94F Q26766707-B516C37F-780A-47B1-A93A-F8A8270675D7 Q26783827-373C5672-D504-43B3-899F-ADE4F329A514 Q26801211-BB2415D7-9530-4E4A-86B5-760F62D8F3C2 Q26823523-42E74967-F1BF-4502-BC23-C2A72D9D518E Q26825172-BD49D9E8-B3F6-4D6C-87AC-23D30EBEA474 Q26827797-B92CAB1B-A8C2-4C97-961E-4B9AE183DC4E Q26851033-4D0AAECB-950F-4E9B-A7B9-768FCD698B39 Q26863748-6EA99E59-5470-4285-B2EE-9C3B2310751A Q27014838-8C90DF0F-7D2C-4FD6-9D0F-7E12A2FF9A82 Q27692609-2837B7F9-9106-4DD0-B532-EFB06DC8FE1D Q28068437-4144D52C-1DD6-4B88-BC2D-917F0659561D Q28076867-D949EB52-8820-4A51-A965-264DDDE4D190 Q28265862-550E85F8-D69D-4076-ADDA-3BFF42326B68 Q28732214-958F2EFD-098C-4B97-85C1-92CFA29D2207 Q30380915-426CB956-7DE4-4F96-9496-57AE6CE70AEF Q30460933-9F76CA31-C8BE-45F3-AB58-38C015ED86F1 Q33395400-99B932E0-34E3-4345-A0C8-E92C3292451E Q33395884-E49C13F5-2FCE-4A01-AD39-EA28FFA1A151 Q33409555-E326BC4E-60E5-4DA1-8CBD-F84E385441D8 Q33420684-7067699E-517B-443C-8823-6C383D0DC19E Q33475230-22F5E205-6DD0-4D6D-82EA-2ECFC84136FB Q33602531-91AB8EE0-B1F7-45F6-87E3-23AED0CED975 Q33655366-FAF5F844-0033-4C33-ACC8-7C8082E3EB39 Q33666679-27AF5106-6534-40EE-9625-CA49EE1B777E Q33681995-0B2DED5D-451C-47A1-8A95-744856B4C5EC Q33710153-173C1F92-6B73-468B-BB55-3D850978CEE6 Q33728605-CDD41625-75FD-4975-819C-27474C3EA27D Q33739313-955F4619-7581-4623-9086-1E9A0D5CAC70 Q33758211-F44A4669-FB85-4AF4-B2B9-1FAEE65CB8DF Q33778970-1691C9FD-32C2-4D1A-8B62-98287001EF08 Q33780701-23CE2845-8F2A-4643-95C3-C3F12A8B8B84 Q34129496-C2F83AF7-CC93-4174-8326-96B5F17E6718 Q34193749-43692F56-94D3-4B01-AD6E-B35B9DCA5538 Q34300621-E81A8A18-81F8-4ACC-93B4-50A73F19FB7D Q34515993-0F4E281B-8456-44B1-990C-71AD005B765F Q34689078-D65C3631-0281-4916-9503-D39239A7CC97 Q34770140-3808ED8A-45A0-4DC4-8081-A9699D3CEA8C Q35025403-50B90B07-8918-4516-80F7-F23C9BC336DE Q35068706-6223E623-96B0-44BC-905D-60C1833BAC2B

P2860

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.

http://www.wikidata.org/entity/Q40198053

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Sorafenib (BAY 43-9006) inhibi ...... poxia in RCC xenograft models.

@en

type

label

Sorafenib (BAY 43-9006) inhibi ...... poxia in RCC xenograft models.

@en

prefLabel

Sorafenib (BAY 43-9006) inhibi ...... poxia in RCC xenograft models.

@en

P1433

Q40198053-0DEA33A7-187A-4BDF-BB1A-71678A399881

P1476

Q40198053-210A5561-7D0A-4319-8885-96CE47F51792

P2093

Q40198053-0326AE14-CC80-4A08-B99E-02B883CA0B45

Q40198053-089C4E02-C8F3-4AD0-AC96-B6D20AE0B677

Q40198053-131B47A6-29F1-476E-8022-6C65A35E322D

Q40198053-25E1DD0C-AC0B-4F8C-9B63-5088D6889889

Q40198053-26A929CE-BE6E-4AAF-8C72-FD66D13C65DA

Q40198053-27EC4515-DF8B-4AB1-8759-E03CC3DF700E

Q40198053-56704ABB-AA95-4C13-BED3-E6CCFD04C5B0

Q40198053-5BE303C2-1C45-434A-89A1-B05672200469

Q40198053-753096B3-A587-4EE2-B32E-4F35F13F75EA

Q40198053-A32F2A26-A989-4942-93B1-CB5D84C38793

P2888

Q40198053-5F28835A-B29D-4C43-A821-75BF4DE9FEA3

P304

Q40198053-DB63A92E-7491-4D3B-8E11-67AD3845208E

P31

Q40198053-B74A05E2-9968-46B5-80A9-B38A2C2E097D

P356

Q40198053-23E652E3-5E98-45F3-829E-49EBB19C98BF

P433

Q40198053-AFB264BC-FD96-4D3F-A7C5-3A12CE983126

P478

Q40198053-6C60D324-AE81-4D56-92AB-4081BFEA4D12

P577

Q40198053-DDDAF12E-4307-423B-809E-811827BC5A9C

P5875

Q40198053-13DD5725-D8B9-4FD0-81CC-ACED7303C18A

P6179

Q40198053-5C96A43C-73EB-4467-9243-26BBC39EC942

P698

Q40198053-2264168A-02B2-42C2-B6E3-1171F490E171

P921

Q40198053-65D5D7E0-AB34-4404-B952-83C25B3E5E1D

Q40198053-EA817186-F9EE-4503-9DC1-712321C8EA69

P356

S00280-006-0393-4

P1433

Cancer Chemotherapy and Pharmacology

P1476

Sorafenib (BAY 43-9006) inhibi ...... poxia in RCC xenograft models.

@en

P2093

Angela McNabola

http://www.w3.org/2001/XMLSchema#string

Arris Henderson

http://www.w3.org/2001/XMLSchema#string

Charles Chen

http://www.w3.org/2001/XMLSchema#string

Christopher A Carter

http://www.w3.org/2001/XMLSchema#string

Dahai Xue

http://www.w3.org/2001/XMLSchema#string

Dean Wilkie

http://www.w3.org/2001/XMLSchema#string

Elizabeth Bortolon

http://www.w3.org/2001/XMLSchema#string

Ian C A Taylor

http://www.w3.org/2001/XMLSchema#string

Jalila Adnane

http://www.w3.org/2001/XMLSchema#string

Joan Levy

http://www.w3.org/2001/XMLSchema#string

P2888

s00280-006-0393-4

P304

561-574

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-006-0393-4

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6640086

http://www.w3.org/2001/XMLSchema#string

P6179

1011237772

http://www.w3.org/2001/XMLSchema#string

P698

17160391

http://www.w3.org/2001/XMLSchema#string

P921